IL191636D0 - Neuropeptide-2 receptor-agonists - Google Patents

Neuropeptide-2 receptor-agonists

Info

Publication number
IL191636D0
IL191636D0 IL191636A IL19163608A IL191636D0 IL 191636 D0 IL191636 D0 IL 191636D0 IL 191636 A IL191636 A IL 191636A IL 19163608 A IL19163608 A IL 19163608A IL 191636 D0 IL191636 D0 IL 191636D0
Authority
IL
Israel
Prior art keywords
neuropeptide
agonists
receptor
Prior art date
Application number
IL191636A
Other versions
IL191636A (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US74807105P priority Critical
Priority to US85524906P priority
Priority to PCT/EP2006/068924 priority patent/WO2007065808A2/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL191636(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL191636D0 publication Critical patent/IL191636D0/en
Publication of IL191636A publication Critical patent/IL191636A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57545Neuropeptide Y
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
IL191636A 2005-12-07 2008-05-22 Neuropeptide-2 receptor-agonists, pharmaceutical compositions comprising them and uses thereof in the preparation of medicaments IL191636A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US74807105P true 2005-12-07 2005-12-07
US85524906P true 2006-10-30 2006-10-30
PCT/EP2006/068924 WO2007065808A2 (en) 2005-12-07 2006-11-27 Neuropeptide-2 receptor-agonists

Publications (2)

Publication Number Publication Date
IL191636D0 true IL191636D0 (en) 2008-12-29
IL191636A IL191636A (en) 2012-10-31

Family

ID=37964711

Family Applications (1)

Application Number Title Priority Date Filing Date
IL191636A IL191636A (en) 2005-12-07 2008-05-22 Neuropeptide-2 receptor-agonists, pharmaceutical compositions comprising them and uses thereof in the preparation of medicaments

Country Status (18)

Country Link
US (2) US7642244B2 (en)
EP (1) EP1962959B1 (en)
JP (1) JP5000663B2 (en)
KR (1) KR101059602B1 (en)
AR (1) AR057222A1 (en)
AT (1) AT549350T (en)
AU (1) AU2006324076A1 (en)
BR (1) BRPI0619573A2 (en)
CA (1) CA2630649A1 (en)
EC (1) ECSP088511A (en)
ES (1) ES2381497T3 (en)
IL (1) IL191636A (en)
MA (1) MA30142B1 (en)
NO (1) NO20082445L (en)
NZ (1) NZ568772A (en)
RU (2) RU2430108C2 (en)
TW (1) TWI321474B (en)
WO (1) WO2007065808A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2430108C2 (en) * 2005-12-07 2011-09-27 Ф.Хоффманн-Ля Рош Аг Neuropeptide-2 receptor agonists
US8299023B2 (en) * 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
MX2011004427A (en) * 2008-11-05 2011-05-31 Hoffmann La Roche Neuropeptide-2-receptor (y-2r) agonists and uses thereof.
WO2011002066A1 (en) 2009-07-02 2011-01-06 武田薬品工業株式会社 Peptide and use thereof
US20130040877A1 (en) * 2009-09-18 2013-02-14 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011045232A2 (en) * 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor (y-2r) agonists
EP2661282A1 (en) * 2011-01-03 2013-11-13 F.Hoffmann-La Roche Ag A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide
EP3339328A1 (en) 2012-07-04 2018-06-27 F. Hoffmann-La Roche AG Anti-biotin antibodies and methods of use
EP2869848B1 (en) 2012-07-04 2016-09-21 F.Hoffmann-La Roche Ag Covalently linked antigen-antibody conjugates
ES2600154T3 (en) 2012-07-04 2017-02-07 F. Hoffmann-La Roche Ag Anti-theophylline antibodies and methods of use
SI3068421T1 (en) 2013-11-15 2019-08-30 Novo Nordisk A/S Selective pyy compounds and uses thereof
BR112016012666A2 (en) 2014-01-03 2017-09-26 Hoffmann La Roche conjugate, antibodies, pharmaceutical formulation and uses of conjugate
RU2693438C2 (en) 2014-01-03 2019-07-02 Ф. Хоффманн-Ля Рош Аг Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
RU2017135520A3 (en) * 2015-04-10 2019-10-11
TW201710284A (en) 2015-06-12 2017-03-16 諾佛 儂迪克股份有限公司 Selective PYY compounds and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
AUPO029096A0 (en) 1996-06-05 1996-07-04 Crc For Biopharmaceutical Research Pty Ltd Npy y2 agonists
US6013633A (en) * 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
WO2004066966A2 (en) 2003-01-17 2004-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Peptide yy analogs
DK1620118T3 (en) 2003-04-08 2014-09-29 Yeda Res & Dev Reversible pegyled medicinal products
CA2545408A1 (en) 2003-11-25 2005-06-16 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US20070244041A1 (en) 2004-02-23 2007-10-18 Reoscience A/S Peptide Yy Analogues
US7410949B2 (en) * 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
WO2007085887A1 (en) 2006-01-27 2007-08-02 Pfizer Products Inc. Pyy agonists and uses thereof
WO2006091505A2 (en) 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Neuropeptide y receptor agonists
RU2430108C2 (en) * 2005-12-07 2011-09-27 Ф.Хоффманн-Ля Рош Аг Neuropeptide-2 receptor agonists

Also Published As

Publication number Publication date
JP2009518349A (en) 2009-05-07
EP1962959B1 (en) 2012-03-14
CA2630649A1 (en) 2007-06-14
WO2007065808A2 (en) 2007-06-14
US8268784B2 (en) 2012-09-18
US20070135351A1 (en) 2007-06-14
MA30142B1 (en) 2009-01-02
RU2430108C2 (en) 2011-09-27
KR20080082672A (en) 2008-09-11
IL191636A (en) 2012-10-31
JP5000663B2 (en) 2012-08-15
US20100137223A1 (en) 2010-06-03
AU2006324076A1 (en) 2007-06-14
EP1962959A2 (en) 2008-09-03
TW200806311A (en) 2008-02-01
NO20082445L (en) 2008-09-03
AR057222A1 (en) 2007-11-21
RU2008127265A (en) 2010-01-20
NZ568772A (en) 2010-05-28
AT549350T (en) 2012-03-15
KR101059602B1 (en) 2011-08-25
BRPI0619573A2 (en) 2011-10-04
US7642244B2 (en) 2010-01-05
WO2007065808A3 (en) 2007-08-02
ES2381497T3 (en) 2012-05-28
RU2011105310A (en) 2012-08-20
TWI321474B (en) 2010-03-11
ECSP088511A (en) 2008-07-30

Similar Documents

Publication Publication Date Title
EP1893196A4 (en) Diarylhydantoin compounds
GB0505941D0 (en) Human-to-mobile interfaces
PT2194043E (en) Processes
EP1872421A4 (en) Terminal-connecting means
PT1856054E (en) Pyrazolylcarboxanilides
DE602006018441D1 (en) Arabinofuranosidasen
DE602006012366D1 (en) Oximester-photoinitiatoren
DE602006013270D1 (en) Prrs-impfstoffe
DE602006021475D1 (en) Carbonylierungsverfahren
DE602006005477D1 (en) Imidazopyridinverbindungen
DE602006017073D1 (en) Aspartylproteasehemmer
PL2332457T3 (en) Dishwashing-machine
HK1176076A1 (en) Anti-glypican-3 antibody --3
DE602006018627D1 (en) Cholesterol-absorptionsinhibitor
GB0503962D0 (en) Compounds
AP2108A (en) Novel biphenylsulfonamides
HK1116776A1 (en) Triazolophthalazines as pde2-inhibitors
DE602006016093D1 (en) Cyanoanthranilamidinsektizide
GB0523969D0 (en) Inductivwe component
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
DE602006015503D1 (en) Luftreinigeranordnung
EP1848299A4 (en) Case
DE602006020169D1 (en) Differential-bogendraht
SI1871749T1 (en) Selurampanel
IL187919D0 (en) 4c

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees